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Background: Reduced innate immunity responses as well as reduced T regulatory activities characterise
bronchial asthma.
Objectives: In this study the effect of budesonide on the expression of TLR4 and TLR2 in T regulatory
lymphocyte sub-population was assessed.
Methods: TLR4 and TLR2 expression in total peripheral blood mononuclear cells (PBMC), in CD4þ/CD25þ
and in CD4þ/CD25 was evaluated, by ﬂow cytometric analysis, in mild intermittent asthmatics (n ¼ 14)
and in controls (n ¼ 11). The in vitro effects of budesonide in modulating: TLR4 and TLR2 expression in
controls and in asthmatics; IL-10 expression and cytokine release (IL-6 and TNF-a selected by a multiplex
assay) in asthmatics were also explored.
Results: TLR4 and TLR2 were reduced in total PBMC from asthmatics in comparison to PBMC from
controls. CD4þCD25þ cells expressed at higher extent TLR2 and TLR4 in comparison to CD4þCD25
cells. Budesonide was able to increase the expression of TLR4, TLR2 and IL-10 in CD4þ/CD25highlyþ cells
from asthmatics. TLR4 ligand, LPS induced Foxp3 expression. Budesonide was also able to reduce the
release of IL-6 and TNF-a by PBMC of asthmatics.
Conclusions: Budesonide potentiates the activity of Treg by increasing TLR4, TLR2 and IL-10 expression.
This event is associated to the decreased release of IL-6 and TNF-a in PBMC treated with budesonide.
These ﬁndings shed light on new mechanisms by which corticosteroids, drugs widely used for the
clinical management of bronchial asthma, control T lymphocyte activation.
© 2015 Elsevier Ltd. All rights reserved.1. Introduction
Asthma is a heterogeneous disorder that is characterized by
variable and largely reversible airﬂow obstruction, airway inﬂam-
mation and hyperresponsiveness. Airway inﬂammation in allergic
asthma is characterized by exaggerated activation of T helper type-
2 (Th2) cells, IgE production and eosinophilia [1]. An increasedratory volume in 1 s; TLR, toll
LPS, lipolysaccharide; LPT,
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a 153, 90146 Palermo, Italy.survival of immune effector cells (eosinophils, macrophages and T
lymphocytes) within the airways contributes to the severity of
asthma [2]. T-lymphocytes play a crucial role in the development of
airway inﬂammation. Particularly, Tregs exert an important role in
the control of T-cell-mediated inﬂammation in asthma [3,4]. Two
major subsets of Tregs are identiﬁed: CD25highly þ Foxp3þ Tregs
and IL-10-producing Tregs. The numbers or function of both Treg
subsets are deﬁcient in patients with atopic allergic diseases
including asthma [5]. Enhanced production of IL-6 induces the in-
crease of allergic inﬂammation via suppression of regulatory T-cells
[6]. In this regard, it has been demonstrated that the pro-
inﬂammatory cytokine IL-6 inhibits the TGFb-induced generation
of Foxp3 Treg [7].
Several epidemiological studies shed light on the possible pro-
tective inﬂuences of natural microbial exposure on atopy and
E. Pace et al. / Pulmonary Pharmacology & Therapeutics 32 (2015) 93e10094asthma development and have led to the formulation of the hy-
giene hypothesis [8]. According to this hypothesis, a constant Th1
triggering balances the immune system, and the removal of these
triggers skews the system toward Th2. The lack of Th1-inducing
factors, i.e. the reduction of pathogen-associated molecular pat-
terns (PAMP), which are detected by cells expressing Toll-like re-
ceptors (TLRs), is associated with the germ-reduced living standard
in the cities of the so-called Western world. This coincides with an
increase of Th2-mediated disorders such as allergic bronchial
asthma and atopic dermatitis in the urban population, while these
disorders are not detected in the rural population [9]. A protective
effect for the development of childhood allergic diseases in rural
population may be also due to the ﬁnding that Treg cells were
signiﬁcantly increased in farm-exposed children after phorbol 12-
myristate 13-acetate/ionomycin and LPS stimulation [10]. Stimu-
lation of innate immunity receptors can also directly inﬂuence the
function of Treg cells. In this regard, it has been demonstrated that
innate immunity receptors (TLRs) modulate the suppressive activ-
ity of naturally occurring CD4(þ)CD25(high) Treg [11,12].
Corticosteroids are the most effective anti-inﬂammatory agents
and topical corticosteroids including budesonide are the recom-
mended therapy by current guidelines for asthma treatment [13].
Corticosteroids act on Tregs increasing IL-10 production [14] and
enhancing IL-10 Treg function [5]. Corticosteroids inhibit T-cell
activation and production of Th2 cytokines [15] and increase T cell
apoptosis [16]. Corticosteroids are able to increase in vivo TLR4
expression in peripheral monocytes of asthmatics [17]. Further-
more budesonide (BUD) increases Foxp3 and IL-10 on CD4þCD25þ
cells from asthmatics [18]. No study assesses the effect of cortico-
steroids on the expression of TLR4 and of TLR2 and IL-10 in
CD4þCD25highlyþ cells and the contextual release of IL-6 and of
TNF-a by peripheral blood mononuclear cells (PBMCs) in
asthmatics.
The objectives of this study were to assess the effects of BUD, a
potent inhaled corticosteroid, on the expression of TLR4, TLR2, and
IL-10 in CD4þCD25highþ lymphocytes (Treg) obtained from asth-
matic patients as well as in IL-6 and TNF-a release by PBMCs.
2. Materials and methods
2.1. Subjects and study design
The studywas approached by in vitro assessments of BUD effects
in asthma. For in vitro evaluations, we selected 14 atopic patients
with mild intermittent asthma, according to the criteria of the
American Thoracic Society [19], and 11 control subjects without
allergic diseases or asthma (Table 1). All asthmatic patients
(Table 1) were characterized by a reversible airway obstruction
assessed by an increase of 12% of forced expiratory volume in 1 s
(FEV1) after inhalation of 200 mg of salbutamol. The asthma diag-
nosis and the assessment of its severity were performed accordingTable 1
Demographic and clinical characteristics of the study population.
Controls
(n ¼ 11)
Mild intermittent
asthmatics (n ¼ 14)
Caucasic race 11 14
Gender (M/F) 5/6 7/7
Age (years) 50 (25e75) percentiles 37 (26e40) 29 (23e38)
FEV1% of predicted percentiles 110 (107
e119)
97 (92e105)
Bronchodilation test: Reversibility
(%) percentiles
e 15 (13e15.7)
Skin prick test (negative/positive) 11/0 0/14
FEV1 ¼ forced expiratory volume in 1 s.to the Global Initiative for Asthma [20]. All recruited subjects were
never-smokers. Atopy was established by aeroallergen skin prick
test (Alk Abello, Hørsholm, Denmark). The following allergens were
tested by skin prick test: dermatophagoydes pteronyssinus, der-
matophagoydes farinae, olive, parietaria judaica, cypress, ragweed,
mugwort (Artemisia Vulgaris), cat, dog, alternaria, claudosporium.
None of the patients recruited for evaluating in vitro effects of BUD
received any corticosteroid treatment. Subjects who had bronchial
or respiratory tract infections during the month before the test
were not included. The study fulﬁlled the criteria of the Ethics
Committee of Policlinico-Giaccone Hospital-Palermo, was
approved (authorisation reference number 7/2013) and was in
agreement with the Helsinki Declaration. All subjects had given
their written informed consent.
2.2. Peripheral blood mononuclear cells (PBMCs) cultures
Peripheral blood mononuclear cells (PBMCs) were isolated from
blood samples (10 ml) of enrolled subjects by Ficoll-Hypaque
(Pharmacia) gradient centrifugation. Cells were suspended in
RPMI 1640 tissue culture medium (Invitrogen Life Technologies)
supplemented with 1% heat-inactivated FCS (Invitrogen Life Tech-
nologies), 2 mM L-glutamine, 20 mM HEPES, 100 U/ml penicillin,
100 mg/ml streptomycin, 5  105 M 2-ME and 85 mg/ml genta-
micin. Viability was tested using trypan blue exclusion.
For assessing in vitro effects of BUD, cells (2  106 cells/ml) were
incubated in culture tubes (Becton Dickinson, Mountain View, CA)
for 24 h either in the absence and in the presence of BUD (B7777
Sigma, St Louis, MO) (108 M ﬁnal concentration). The concentra-
tion range of BUD 108 M and incubation time 24 h were selected
on the basis of the results of a previous study [18]. In some ex-
periments cells were cultured for 24 h with LPT (Sigma) (100 mg/ml
for 18 h) and with LPS (Sigma) (1 mg/ml for 18 h) alone and com-
bined with BUD.
2.3. Flow cytometry analysis for surface markers
PBMCs were stained with FITC anti-human CD4, PE-Cy5 anti-
human CD25 and PE anti-human TLR4 or TLR2 mAbs by using FACS
analysis (Becton Dickinson FACSCalibur System). All monoclonal
antibodies (mAb) were from Becton Dickinson PharMingen eBio-
scence. Negative controls were performed using an isotype control
antibody at the same titer as the primary antibodies (Becton
Dickinson PharMingen). Lymphocytes were gated by forward and
side scatter as previously described [18] and analysis was done on
100,000 acquired events for each sample using CellQuest acquisi-
tion and data analysis software (Becton Dickinson). Cell debris and
dead cells were excluded from the analysis by forward and side
scatter. The expression of TLR4 and of TLR2 was performed on total
PBMC (no gating) or on lymphocyte subpopulations (CD4þCD25
and CD4þCD25þ). The gate for lymphocytes was selected as pre-
viously described in a paper from our group [18]. In the experi-
ments evaluating the effect of BUD, the expression of TLR2 and of
TLR4 was assessed also in CD4þCD25highlyþ cells
(positivity > 102).
2.4. Intracellular cytokine staining
For the detection of intracellular cytokine IL-10, PBMC were
cultured overnight (10 h) with GolgiStop (2 mM ﬁnal concentration)
(BD PharMingen). The cells were stained with mAbs against CD4
FITC and CD25 PE-Cy5 in PBS containing 1% FCS and 0.1% Na azide
for 30 min at 4 C. Cells were washed twice in PBS with 1% FCS and
ﬁxed with PBS containing 4% paraformaldehyde for 20 min at room
temperature. After two washes in permeabilization buffer (PBS
Fig. 1. Expression of TLR2 in PBMC. PBMC from controls (n ¼ 8) and from mild
intermittent asthmatics (n ¼ 11) were isolated and were assessed for TLR2 expression
by ﬂow-cytometry. Data are expressed as percentage of positive cells. Horizontal bars
inside boxes represent the median values and limits of boxes represent the 25th and
75th percentiles. *p < 0.05 Mann Whitney test for comparisons between controls and
asthmatics.
Fig. 2. Expression of TLR4 in PBMC. PBMC from controls (n ¼ 8) and from mild
intermittent asthmatics (n ¼ 11) were isolated and were assessed for TLR4 expression
by ﬂow-cytometry. Data are expressed as percentage of positive cells. Horizontal bars
inside boxes represent the median values and limits of boxes represent the 25th and
75th percentiles. *p < 0.05 Mann Whitney test for comparisons between controls and
asthmatics.
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4 C, the cells were stained with 0.25 mg of PE anti-human IL-10
antibody (BD PharMingen). After two more washes in PBS con-
taining 1% FCS, the cells were analysed by ﬂow cytometry. The
expression of IL-10 was assessed in CD4þCD25highlyþ cells.
2.5. Intracellular Foxp3 staining
PBMC were simultaneously stained with PE anti-human CD4
and PE-Cy5 anti-human CD25 (BD PharMingen). Cells were ﬁxed
and permeabilized using the BD PharMingen human Foxp3 Buffer
Set, following the manufacturer's recommended assay procedure.
Finally, the cells were stained with FITC anti-human Foxp3 (BD
PharMingen).
2.6. Multi-analyte ELISArray
Cells (2  106/ml) were incubated in culture tubes (Becton
Dickinson, Mountain View, CA) for 24 h either in the absence and in
the presence of BUD (108 M ﬁnal concentration) and cell super-
natants were collected. For the simultaneous detection of 12 cy-
tokines (IL-2, IL-4, IL-5, IL-6, IL-10, IL-12, IL-13, IL-17A, IFNg, TNF-a,
G-CSF, TGFb1), in cell supernatants, a multi-analyte ELISArray TH1/
TH2/TH17 (Qiagen, Valencia, CA), using a standard sandwich ELISA
protocol, was performed following manufacturer's instructions.
The expression of the each cytokine was expressed as absorbance.
Absorbance values were corrected for dilution of the samples and
negative control absorbance was subtracted. Cytokines with a
baseline absorbance less than 0.1 (IL-2, IL-4, IL-5, IL-10, IL-12, IL-13,
IFNg, G-CSF) were excluded.
2.7. Statistical analysis
Data are expressed as medians and 25e75 percentiles or as
mean ± SD. All the statistical analyses were performed using the
StatView 5.0.1 software. A non-parametric Mann Whitney test for
comparisons between the two recruited groups was applied. Sta-
tistical analysis of the in vitro effects of BUD was performed by
Wilcoxon test or by paired t test. KolmorogoveSmirnov Normality
test was initially performed to assess whether parametric analyses
of data could be performed. p < 0.05 was accepted as statistically
signiﬁcant.
3. Results
3.1. Demographic characteristics of the subjects
The demographic characteristics, the clinical and functional
evaluations of the studied patients are shown in Table 1.
3.2. TLR2 and TLR4 expression by PBMCs
Initially we tested whether a different expression of innate
immunity receptors, TLR2 and TLR4, was present on PBMCs from
controls and asthmatics. TLR2 (Fig. 1) and TLR4 (Fig. 2) expression
was signiﬁcantly reduced in asthmatics in comparison to controls.
3.3. TLR2 and TLR4 expression by lymphocyte subpopulations
We next assessed the distribution of TLR2 and TLR4 expression
in CD4þCD25þ and in CD4þCD25 lymphocyte subpopulations.
As shown in Fig. 3AeB, CD4þCD25þ cells highly expressed TLR2
and TLR4 molecules in comparison to CD4þCD25 cells in both
controls and in asthmatics. Representative dot plots are shown in
Figure S1. CD4þCD25þ cells highly expressed Foxp3 molecule incomparison to CD4þCD25 cells in both controls and in asthmatics
conﬁrming that Treg cells are mainly present on CD4þCD25þ cells
(Fig. 4). Furthermore, the expression of Foxp3 on CD4þCD25þ cells
was signiﬁcantly lower in asthmatics than in controls (p < 0.03;
Mann Whitney test). Among the CD4þCD25þ cells, the higher
percentage of Foxp3þ cells was present in CD4þCD25highlyþ cells
(CD25 lowþ 6.2 ± 2.2; CD25highlyþ 14.2 ± 4.5).3.4. Effect of BUD on TLR2 and TLR4 expression by
CD4þCD25highlyþ cells
Since the expression of TLR in Treg may regulate the activity of
these cells [10], the effect of BUD on the expression of both TLR2
and TLR4 in CD4þCD25highlyþ cells from asthmatics was also
explored.
BUD was able to signiﬁcantly increase the expression of TLR2
(Fig. 5) and of TLR4 (Fig. 6) in CD4þCD25highlyþ cells. BUDwas not
Fig. 3. Expression of TLR2 and TLR4 in lymphocyte subpopulations. PBMC from controls (n ¼ 8) and from mild intermittent asthmatics (n ¼ 11) were isolated and the total
lymphocytes were gated by forward and side scatter. The expression of TLR4 and of TLR2 was assessed on lymphocyte subpopulations (CD4þCD25 and CD4þCD25þ). Data are
expressed as percentage of positive TLR2 and TLR4 in lymphocyte subpopulations of controls (C) and of asthmatics (D). Horizontal bars inside boxes represent the median values
and limits of boxes represent the 25th and 75th percentiles. *p < 0.05 Wilcoxon test for comparing TLR2 and TLR4 expression in CD4þCD25þ and in CD4þCD25 cells within
controls and asthmatics.
Fig. 4. Expression of Foxp3 in lymphocyte subpopulations. PBMC from controls (n ¼ 8)
and from mild intermittent asthmatics (n ¼ 11) were isolated and the total lympho-
cytes were gated by forward and side scatter. The expression of Foxp3 was assessed on
lymphocyte subpopulations (CD4þCD25 and CD4þCD25þ). Data are expressed as
percentage of Foxp3 in lymphocyte subpopulations of controls and of asthmatics.
Horizontal bars inside boxes represent the median values and limits of boxes represent
the 25th and 75th percentiles. *p < 0.03; MannWhitney test comparing the expression
of Foxp3 in CD4þCD25þ cell population between controls and asthmatics.
Fig. 5. Effect of BUD on the expression of TLR2 in CD4þCD25highlyþ cells from asthmatics. PBMC from mild intermittent asthmatics (n ¼ 11) were cultured with/without BUD and
were assessed for TLR2 expression by ﬂow-cytometry in CD4þCD25highlyþ cells. CD4þCD25highlyþ cells were gated as shown in A. Data are expressed as percentage of positive
cells (B). Horizontal bars inside boxes represent the median values and limits of boxes represent the 25th and 75th percentiles. *p < 0.05 Wilcoxon test.
Fig. 6. Effect of BUD on the expression of TLR4 on CD4þCD25highlyþ cells from
asthmatics. PBMC from mild intermittent asthmatics (n ¼ 11) were cultured with/
without BUD and were assessed for TLR4 expression by ﬂow-cytometry in
CD4þCD25highlyþ. Data are expressed as percentage of positive cells. Horizontal bars
inside boxes represent the median values and limits of boxes represent the 25th and
75th percentiles. *p < 0.05 Wilcoxon test.
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Fig. 7. Effect of BUD on the expression of TLR2 and of TLR4 on lymphocytes from
controls. PBMC from controls (n ¼ 3) were cultured with/without BUD and were
assessed for TLR2 and TLR4 expression by ﬂow-cytometry. Data are expressed as
percentage of positive cells. Horizontal bars inside boxes represent the median values
and limits of boxes represent the 25th and 75th percentiles. *p < 0.05 Wilcoxon test.
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CD4þCD25þ lymphocytes from controls (Fig. 7).3.5. Effect of TLR2 and TLR4 ligands on Foxp3 expression in
lymphocytes
Foxp3 is a transcription factor speciﬁcally associated to regula-
tory activities. We next tested whether a TLR2 ligand, LPT and a
TLR4 ligand (LPS) induced Foxp3 expression on lymphocytes from
both controls and asthmatics. LPS was able to signiﬁcantly induce
Foxp3 expression in total lymphocytes and in CD4þCD25 lym-
phocytes from asthmatics. LPS was also able to signiﬁcantly induce
Foxp3 expression in CD4þCD25 lymphocytes from controls. No
signiﬁcant effect was observed for LPT (Fig. 8).The combined
presence of TLR2 and TLR4 ligands and BUD did not increase Foxp3
expression (data not shown).3.6. Effect of BUD on IL-10 expression by CD4þCD25highþ cells
Corticosteroids act on CD4þCD25þ cells from asthmatics
increasing IL-10 production [12,18]. In CD4þ/CD25highlyþ cells
from asthmatic patients BUDwas able to increase the percentage of
IL-10 positive cells (Fig. 9).Fig. 8. Effect of TLR2 and TLR4 ligands on the expression of Foxp3 on lymphocytes from cont
cultured with/without a TLR2 ligand (LPT) and a TLR4 ligand (LPS) and were assessed for Fo
expression on CD4þCD25 lymphocytes. Data are expressed as percentage of positive cells3.7. Effect of BUD on IL-6 and TNF-a release by PBMCs from
asthmatics
The simultaneous detection of 12 different Th1/Th2/Th17 cyto-
kines was performed. Among the analysed cytokines only IL-6 and
TNF-a were evaluable (absorbance values more than 0.1) at base-
line and were modulated by BUD. When PBMCs from asthmatics
were incubated with BUD a signiﬁcantly reduced release of IL-6
(Fig. 10) and of TNF-a (Fig. 11) was observed. IL-17 and TGFb1 had
absorbance values at the baseline more than 0.1 but were not
signiﬁcantly modulated by BUD (data not shown).4. Discussion
Allergic diseases including bronchial asthma are not conﬁned to
the area where they originated but they involve also systemic cir-
culation [21]. The present study demonstrates that BUD, an inhaled
corticosteroid widely used for the management of bronchial
asthma, controls asthma inﬂammation by modulating TLR2 and
TLR4 and IL-10 expression in CD4þ/CD25highlyþ cells as well as IL-
6 and TNF-a release in PBMC of asthmatics. These mechanisms of
action of BUD provide further understanding on new mechanisms
by which corticosteroids control T lymphocyte activation, an
important target of anti-inﬂammatory drugs.
The hygiene hypothesis is considered the most reasonable
explanation for the allergy epidemics inWestern countries that has
occurred over the past few decades [8]. The immunological
mechanisms on the basis of the hygiene hypothesis are a missing
immune deviation of allergen speciﬁc responses from a Th2 to a
Th1 proﬁle and a reduced activity of Treg cells [10]. Innate immu-
nity receptors (TLRs) may directly modulate the suppressive ac-
tivity of naturally occurring CD4(þ)CD25(highlyþ) Treg [11,12].
Accordingly, Treg cells are increased in farm-exposed children after
LPS stimulation, the agonist of TLR4 [10]. Furthermore, TLR4 sig-
nalling may promote the induction of IL-10-secreting type 1 regu-
latory Tcells [22] and a reduced activation [23] or expression [24] of
speciﬁc TLRs may account for a missing immune deviation of
allergen speciﬁc responses from a Th2 to a Th1 proﬁle. In this re-
gard, a previous study demonstrates that an up-regulation of TLR2
and TLR4 expression in PBMCs from asthmatics is associated to
reduced pro-inﬂammatory responses to allergens [25]. On the basis
of these concepts, we initially evaluated the expression of TLR2 and
TLR4 and demonstrated a reduced expression of these receptors in
PBMCs, i.e. total lymphocytes and monocytes from untreated
asthmatics in comparison to controls. Since the expression of TLR2rols and from asthmatics. PBMC from controls (n ¼ 3) and from asthmatics (n ¼ 3) were
xp3 expression by ﬂow-cytometry. A. Foxp3 expression on total lymphocytes. B. Foxp3
(mean ± SD). *p < 0.05 paired t test.
Fig. 9. Effect of BUD on the expression of IL-10 in CD4þCD25highlyþ cells from
asthmatics. PBMC from mild intermittent asthmatics (n ¼ 11) were cultured with/
without BUD and were assessed for IL-10 expression by ﬂow-cytometry in
CD4þCD25highlyþ cells. Data are expressed as percentage of positive cells. Horizontal
bars inside boxes represent the median values and limits of boxes represent the 25th
and 75th percentiles. *p < 0.05 Wilcoxon test.
Fig. 10. Effect of BUD on IL-6 release by PBMC from asthmatics. PBMC from mild
intermittent asthmatics (n ¼ 3) were cultured with/without BUD and IL-6 release was
assessed by multi-analyte ELISArray. Data are expressed as absorbance (mean ± SD).
*p < 0.05 paired t test.
Fig. 11. Effect of BUD on TNF-a release by PBMC from asthmatics. PBMC from mild
intermittent asthmatics (n ¼ 3) were cultured with/without BUD and TNF-a release
was assessed by multi-analyte ELISArray. Data are expressed as absorbance
(mean ± SD). *p < 0.02 paired t test.
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trated in CD4þCD25þ cells, we further assessed whether BUD
affected the expression of TLR2 and TLR4 innate immune receptors
in a subpopulation of CD4þCD25þ cells, i.e. on CD4þCD25highlyþ
cells, the naturally occurring Treg [11,12]. We demonstrated that
BUD increases the expression of both TLR2 and TLR4 in
CD4þCD25highlyþ from recruited asthmatics but not from
recruited controls. Consequently, BUD via the up-regulation of
innate immune receptors on Treg may have the potential to
ameliorate the Th2 immune deviation of allergic subjects. To
further demonstrate this effect, we stimulated lymphocytes from
asthmatics and controls with TLR2 and TLR4 ligands. It was
demonstrated here that LPS, a TLR4 ligand is able to increase Foxp3
in CD4þCD25 in asthmatics as well as in controls. This phenom-
enon may be relevant in the control of bronchial inﬂammation
since CD4þ/CD25 T lymphocytes ectopically expressing Foxp3
acquire the function to control inﬂammation in experimentally
induced inﬂammatory bowel disease and to down-regulate the
proliferation of CD4þ/CD25 T lymphocytes in vitro [26].
Although it has been previously demonstrated by our group that
BUD in vitro is able to signiﬁcantly increase the percentage of Foxp3
positive cells in CD4þCD25 [18], the combined presence of TLR2
and TLR4 ligands and BUD did not induce any effects on Foxp3
expression. Further experiments are needed to clarify this
phenomenon.
T regulatory activities are mainly related to naturally occurring
CD4þ/CD25þ Tregs and to CD4þ/CD25 inducible Tregs [27]. It has
been previously demonstrated that BUD increases costimulatory
activities in CD4þ/CD25þ further supporting the concept that this
drug is effective in controlling T lymphocyte activation also
improving the function and the activities of the Tregs. Here, we
conﬁrm that Foxp3, a transcription factor typically associated to
Tregs activities, is expressed on CD4þ/CD25þ [28] and more on
CD4þCD25highlyþ. This natural CD4þ/CD25þ subset is thymus-
born, constitutively expresses IL-10 mRNA, does not produce IL-2,
and is resistant to apoptosis [28].
T regulatory activities have the potential to suppress pathogenic
Th2 responses thus preserving lung integrity [28] and may be
defective or overridden in patients with allergic diseases including
asthma [5]. The levels of Foxp3 mRNA in BAL from children with
asthma are lower than in healthy controls, positively correlate with
FEV1 and, after 4 weeks of treatment with inhaled corticosteroids,
signiﬁcantly increase [3]. Furthermore, in severe asthmatics, the
Foxp3 protein expression in PBMC correlates with the FEV1 values
and with the symptom score [29]. Here we conﬁrm as previously
reported [30] that although the total numbers of
CD4þCD25highlyþ cells in controls and in asthmatics were similar
(data not shown), CD4þCD25þ cells from asthmatics have lower
expression of Foxp3 in comparison to controls. As previously re-
ported [18], not signiﬁcant differences were observed for the
numbers of CD4þCD25þ cells between asthmatics and controls.
BUD in vitro is able to signiﬁcantly increase Treg activities and to
down-regulate the lymphocyte proliferation upon allergen stimu-
lation [18,31]. Tregs control effector immune responses through a
diverse array of mechanisms including secretion of the anti-
inﬂammatory cytokines TGF and IL-10 [32]. IL-10 is essential not
only for suppression of effector cells by Treg cells but also for their
differentiation [27]. IL-10, produced by a number of different cells,
affecting antigen presenting cell function, dendritic cell maturation
as well as the activation of co-stimulatory molecules, can inhibit
both Th1 and Th2 type responses [14]. IL-10 activates tyrosin
phosphatase 1 which dephosphorylates rapidly CD28 and ICOS co-
stimulatory receptors [33]. We see here that BUD is able to increase
the expression of IL-10 in CD4þ/CD25þ cells. A rapid switch and
expansion of IL-10-producing cells and the use of multiple
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tolerance to a high dose of allergens in non-allergic individuals [34].
Moreover, the present study demonstrates for the ﬁrst time that
BUD is able to signiﬁcantly reduce the release of IL-6 and TNF-a by
PBMCs from asthmatics. TNF-amay be released by CD4þ and CD8þ
lymphocytes in peripheral blood compartment [35].
IL-6 is a small size glycoprotein (21 KDa) produced by cells from
the innate immune system (e.g. macrophages, dendritic cells, mast
cells, neutrophils), but also by B cells and, to a lesser extent, by
some CD4 effector Th cells [36]. Increased levels of IL-6 in serum in
asthmatic patients, may contribute to asthma pathogenesis, regu-
lating the effector CD4 T cell fate, promoting IL-4 production during
Th2 differentiation, inhibiting Th1 differentiation and, together
with TGFb, promoting Th17 cell differentiation and suppressing
regulatory T-cells [6,37,38]. In this regard, it was found that TGFb
induces the generation of Foxp3 Treg, which were completely
inhibited by a pro-inﬂammatory cytokine IL-6 [7]. In addition, it has
been shown that the levels of IL-6 in sputum inversely
correlate with FEV1 values [39].
Taken together these ﬁndings suggest that IL-6 is likely to be
directly involved in the pathogenesis of asthma and in the pro-
gressive loss of lung function observed in patients who remain
untreated; i.e. IL-6 is likely a potential target for new treatments for
this important disease.
Moreover, IL-6 has been considered a general marker of
inﬂammation together with TNF-a and IL-1b, two other classical
inﬂammatory cytokines. TNF-a has been implicated in the patho-
genesis of asthma, and neutralization of TNF-a is an effective
therapy for inﬂammatory diseases [40]. In children the up-
regulation of TNF-a expression is associated to a more severe
course of respiratory syncytial virus infection as well as to the onset
of asthma [41]. Furthermore, circulating levels of TNF-a are
increased in severe asthmatics more than in mild and moderate
asthmatics [42]. Unfortunately, the need to recover millions of cells
to perform all the analyses to test BUD effects did not allow us to
extend the study to lymphocytes isolated from induced sputum or
bronchoalveolar lavages.
In conclusion, these results suggest that BUD is effective in
controlling asthma inﬂammation up-regulating the expression of
TLR2/4 and IL-10 in Treg and down-regulating the release of pro-
inﬂammatory cytokines (IL-6 and TNF-a) with an important role
in the pathogenesis of asthma. Future studies are needed to clarify
whether these immune-modulatory effects of BUD are shared or
not with other inhaled steroids.Acknowledgements
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